Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
With >2 years of follow up, Japanese patients from the international phase III CheckMate 025 study had a higher response rate with nivolumab versus everolimus and a favorable safety profile.
Japanese journal of clinical oncology